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Abstract 
Background:   Minimizing endogenous estrogen production and activity in women at high risk for 
breast cancer is a prominent approach to prevention of the disease. This is currently accomplished 
either by administration of aromatase inhibitors, which decrease the synthesis of estrogen from its 
androgen precursors in peripheral tissues, or by  selective-estrogen-receptor-modulators, which 
block the binding of estrogen to its cellular receptors in breast epithelium.  A number of clinical 
trials have shown that this approach does indeed reduce the incidence of breast cancer. 
Unfortunately, these drugs often produce adverse effects on the quality of life, with 
musculoskeletal, vasomotor, and gynecological symptom resulting from the acutely decreased 
levels of estrogens. As a consequence, they have been poorly accepted by many women, even those 
that are at high risk for breast cancer according to risk-prediction models.                                                                                                                                                      
Discussion: We propose a novel alternative approach to decreasing estrogen production at a 
biochemically earlier  stage:  suppression of ovarian production of the androgen precursors of 
estrogens by administration of long-acting gonadotropin-releasing hormone (GnRH) analogues, 
which inhibit the synthesis of gonadotropins and thereby suppress ovarian function. The optimal 
subjects for this approach would be women with high blood levels of testosterone,  marker of 
excessive ovarian androgen production and recognized factor of risk for breast cancer.  The specific 
target population would be elderly postmenopausal women, since breast cancer incidence increases 
with age and reaches its maximum around the age of seventy years .  
Summary: anti-estrogens counter increased estrogen formation and activity, which are 
consequences of excessive androgen production. We propose to  counter  the source of androgen 
excess in women with ovarian stromal hyperplasia, thus reducing the substrate for estrogen 
formation without completely inhibiting estrogen synthesis. Testosterone levels are measured at 
baseline to identify women at risk and during the follow-up to evaluate the effectiveness of therapy. 
Available evidence indicates that  GnRH analogues can be safely used  for breast cancer prevention 
in postmenopausal women. 
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Background  
A large body of evidence points to estrogens as promoters of breast cancer development. This has 
led to attempts at cancer prevention through diminution of the impact of estrogen on the breast, 
either by administration of aromatase inhibitors, such as anastrozole or letrozole, which inhibit the 
synthesis of estrogens from their androgen precursors, or by administration of selective estrogen-
receptor modulators (SERMs ), such as tamoxifen or raloxifen, which block the binding of 
estrogens to their cellular receptors. Clinical trials have shown that applying this approach to 
women at high risk for breast cancer does indeed reduce the incidence of the disease [3-7].   
Unfortunately, these drugs often produce adverse effects on the quality of life, with 
musculoskeletal, vasomotor, and gynecological symptoms resulting from acutely decreased levels 
of estrogen [3-6]. As a consequence, they have been poorly accepted by many women [8-10], even 
those that are at high risk for breast cancer according to risk-prediction models [11-14]. 
In the present paper, we propose a novel alternative approach to breast cancer prevention that is 
virtually devoid of severe adverse events, namely  suppression of ovarian production of the 
androgen precursors of estrogen by administration of long-acting gonadotropin-releasing hormone 
(GnRH) analogues, which inhibit the secretion of luteinizing hormone (LH), the necessary stimulus 
to ovarian androgen production. That this might be an effective approach was suggested by the 
extensive evidence  that women with breast cancer often have interstitial-cell hyperplasia of the 
ovaries, with resulting increased synthesis of androgens, which is often reflected in elevated blood 
testosterone levels [20].  Determining the blood testosterone levels of potential patients would 
delineate the women who would be optimal candidates for our proposed approach. The prime target 
population would be elderly postmenopausal women, since breast cancer incidence increases with 
age and reaches its maximum around the age of seventy years [21,  22].  
In the next section we describe the statement of our proposal and discuss the role of androgen 
excess in breast cancer, the endocrine function of the  postmenopausal ovary, the identification of 
women at increased risk, and the tolerability and side-effects of GnRH analogues.  
 
Discussion   
Statement of our proposal 
Our proposal develops from the evidence that: aromatization of androgen precursors, 
androstenedione and testosterone, is an obligatory step in the synthesis of estrogens, estrone and 
estradiol, respectively [15]; high circulating androgen levels are a known factor of risk for 
postmenopausal breast cancer that can stimulate cancer growth by conversion into estrogens [16-
19]; and the postmenopausal ovary is an important source of excessive androgen production which 
originates from the ovarian interstitial-cell hyperplasia frequently present  in breast cancer patients 
[20]. 
We assume that anti-estrogens are effective in countering increased estrogen formation and activity, 
which are consequences of excessive androgen production, and suggest directly countering  the 
source of androgen excess in women with ovarian stromal hyperplasia, thus reducing the substrate 
for estrogen formation without completely inhibiting estrogen synthesis and function. 
Inhibition of ovarian androgen production can be accomplished by administering long-acting GnRH 
analogues, which induce medical castration by inhibiting the synthesis of gonadotropins. The target 
population includes healthy  women in natural menopause, with intact ovaries, 60 years of age or 
older, at increased risk of breast cancer according to one of the validated risk-prediction models, 
and with high  serum testosterone levels. Elevated serum testosterone levels are a good marker of 
excessive ovarian androgen production [20] and a recognized factor of risk for breast cancer [16-
19]. The availability of a risk factor that is powerful and that can be corrected, is useful to identify a 
distinct subset of women at risk, to evaluate the effectiveness of treatment, and to personalize the 
treatment schedule according to the necessities of each subject. 
Circulating testosterone levels should be regularly checked every six to twelve months in women to 
whom GnRH  analogues are administered; the treatment should be interrupted when blood 
testosterone levels return to normal and should be resumed when they rise again after the initial 
decrease. 
 
The role of androgen excess in breast cancer 
The androgen-excess theory, developed in studies by our group over the last 45 years [20], suggests 
a central role for androgens in breast cancer development. Androgen excess can stimulate breast 
cancer growth by three principal mechanisms: increased conversion into estrogens, which directly 
stimulate estrogen receptor (ER)-positive tumors; direct tumor stimulation by binding to androgen 
receptors (AR) in ER-negative/AR-positive tumors; and increased synthesis of epidermal growth 
factor, which stimulates cancer growth by binding to its own receptor in the ER-negative/AR-
negative tumors [23, 24]. 
A series of  prospective studies in healthy postmenopausal women have shown that elevated blood 
androgen levels  are associated with increased risk of breast cancer [16-19].  In these same studies, 
increased risk of breast cancer was also found associated  with high serum levels of estrogens, a 
finding consistent with increased formation of estrogens by women with high levels of their 
androgen precursors.   Evidence that the effect of increased androgen levels in favoring the 
development of estrogen-dependent breast cancers is a direct one is provided by the finding of a 
strong relationship between blood testosterone levels and the ER content of tumors in contrast to the 
weak relationship of blood estradiol levels to ER content [25, 26]. 
 
Endocrine function of the postmenopausal ovary 
About 50% of circulating testosterone is produced in equal amounts by the ovary and the adrenals; 
the remaining 50% is produced in peripheral tissues by conversion from androstenedione [27, 28]. 
Androstenedione is synthesized in the ovary and the adrenals, and in peripheral tissues by 
conversion from adrenal androgen precursors, dehydroepiandrosterone (DHEA) and  
dehydroepiandrosterone-sulfate (DHEAS) [27, 28]. 
During a woman’s lifespan, blood testosterone levels decrease with age from the twenties till just 
before menopause [29, 30], do not change during the menopausal transition [30-32] and then 
increase slightly in the late postmenopausal years [32-34]. In contrast, the blood levels of DHEA 
and DHEAS decline steadily with age from the early twenties regardless of menopausal status [30, 
31]. 
The postmenopausal ovary continues to secrete large amounts of testosterone and  moderate 
amounts of androstenedione and DHEA well into old age [28, 32, 33, 35, 36]; the androgen 
production occurs in the interstitial cells of  the ovarian stroma under the stimulus of  LH [35, 37, 
38]. Ovarian stromal hyperplasia  is a characteristic feature of breast cancer patients, as was 
reported for the first time by Sommers and Teloh in 1952 [39].  Our early studies in the 1970s [20] 
showed  that such hyperplasia was constantly present in the ovaries of breast cancer patients with 
supranormal urinary testosterone excretion who underwent oophorectomy, either prophylactically, 
to prevent disease progression, or therapeutically, for treatment of metastases. In those patients, 
independent of their menopausal status,  testosterone levels usually reverted to normal after the 
ovaries were removed, and metastases often regressed  [20]. Different degrees of stromal 
hyperplasia, mild, medium, and severe,  have been frequently found in postmenopausal women 
oophorectomized for gynecological disorders and the concentrations of testosterone and 
androstenedione in the ovarian veins were found to be  positively associated with the degree of 
stromal hyperplasia [40-42]. A significant reduction of testosterone and androstenedione circulating 
levels has been constantly reported after oophorectomy [32, 33, 35, 36, 40-42]. 
A study of BRCA1 and BRCA2 mutation carriers showed a highly significant reduction of breast 
cancer risk in women who had oophorectomy after natural menopause, whereas women with natural 
menopause who were not oophorectomized showed no such effect [43]; the authors suggested that 
the reduction of circulating testosterone levels after oophorectomy might account for its protective 
effect [43]. In a recent study [44], blood levels of androgens and estrogens were measured in a 
group of women who underwent natural menopause without oophorectomy and in two groups of 
women who underwent oophorectomy either at premenopausal age or after natural menopause. 
Significantly lower testosterone levels were found in both  oophorectomized groups than in women 
with intact ovaries, while the levels of estradiol, estrone, estrone-sulfate and DHEAS did not differ 
among the three groups [44]. 
It appears, therefore, that the postmenopausal ovary is an endocrine organ that produces androgens 
well into old age; that ovarian stromal hyperplasia increases androgen production; that blood 
testosterone level is a good marker of ovarian androgen production; and that oophorectomy after the 
natural menopause significantly reduces the blood testosterone levels and may be protective against 
breast cancer. 
 
Identification of women at increased risk for breast cancer 
Several breast cancer risk-prediction models are available to identify women at high risk. In these 
models, risk is calculated by awarding a score to known risk factors including  reproductive and 
family history, previous breast biopsies and others [11-14]. Although effective in predicting 
absolute  risk, these models have limited ability to discriminate between women who will develop 
breast cancer and those who will not [12]. Tworoger et al. [45] have recently shown that the 
inclusion of blood levels of sex steroids in the  models improves risk prediction, a finding that 
supports our proposal to evaluate serum testosterone levels for identifying a subset of women at 
increased risk. 
An estimate of the number of cancers that could be prevented by correcting androgen excess in 
otherwise healthy women can be obtained by data of our studies in a cohort of 534 postmenopausal 
breast cancer patients [26].  High testosterone levels were found in about half of ER-positive 
patients and in about 6% of ER-negative patients of our cohort [23, 46]. It has been reported [47] 
that a single measurement of testosterone can predict breast cancer risk for up to twenty years in 
healthy women, therefore we can assume that the high testosterone levels detected in patients of our 
cohort were present before the diagnosis of cancer and contributed to the development of about 
50% of ER-positive tumors and of a small percentage of ER-negative tumors. 
Testosterone levels are commonly measured by radioimmunoassay (RIA), a method that may be 
appropriate for identifying women with elevated serum testosterone values in prospective studies 
but that has been criticized for its lack of the accuracy and sensitivity required to measure the low 
blood testosterone levels commonly present in normal women and children [49-52]. This problem 
stimulated the development of mass spectrometry techniques for such measurements. Currently, 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method for 
measurement of low testosterone and estradiol concentrations [52] and may be preferable to RIA 
also because of its ability to simultaneously quantitate several steroids in a single run 
Prospective studies in healthy postmenopausal women have reported an association of elevated 
levels of estrogens and androgens with increased risk of breast cancer, regardless of the method 
used for steroid quantitation, whether direct RIA, RIA after prior extraction and purification of the 
sample, or mass spectrometry [Endogenous Hormones and Breast Cancer Collaborative Group 2015]. In our 
proposal, we suggest selecting normal postmenopausal women with elevated serum testosterone 
levels for prophylactic treatment with GnRH analogues, and in order to do this we need to 
determine the best cut-off value between normal testosterone levels and elevated levels. In studies 
of postmenopausal breast-cancer patients [46, Berrino et al. 2005, Micheli et al. 2007], we 
measured blood testosterone levels by direct RIA and found that patients with levels above the 
median value for the group were at higher risk of relapse than patients below the median value. In 
those studies, carried out at different times and in different groups of breast-cancer patients, the 
median value of blood testosterone concentration was consistently 0.40 ng/ml, which corresponds to 
the lower boundary of the uppermost tertile in three hundred healthy postmenopausal women 
recruited in a previous study [48]. Since that cut-off value distinguished two groups of patients with 
different outcomes, it seems possible to use it to characterize the women in the general population 
who have elevated levels of testosterone and are therefore at higher risk for breast cancer. 
 
Endogenous Hormones and Breast Cancer Collaborative Group: Steroid hormone measurements from different 
types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of 
eighteen prospective studies. Steroids 2015, 99 49–55 
 
Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A, Berselli E, Muti P, Secreto G:Serum 
testosterone levels and breast cancer recurrence. Int J Cancer 2005, 113:499-502; 
 
Micheli A, Meneghini E, Secreto G, Berrino F, Venturelli E, Cavalleri A, Camerini T, Di Mauro MG, Cavadini E, De 
Palo G, Veronesi U, Formelli F: Plasma testosterone and prognosis of postmenopausal breast cancer patients. J 
Clin Oncol 2007, 25:2685-90. 
 
 
Tolerability and side-effects of GnRH analogues 
Long-acting  GnRH  analogues inhibit the pituitary synthesis of the gonadotropins, LH and follicle 
stimulating hormone (FSH), and thereby deprive the ovaries of the necessary stimulation for 
androgen and estrogen production. Giving these agents is commonly referred to as “medical 
oophorectomy”;  the effect is reversible when the GnRH analogue treatment is stopped.  
The usual use of these agents is in premenopausal women with gynecological disorders such as 
uterine fibroids or endometriosis, in men with prostate cancer, and in premenopausal early breast 
cancer patients as adjuvant therapy of ER-positive tumors. They have also been used  in 
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premenopausal women with metastatic breast cancer, where they achieve responses similar to those 
of surgical oophorectomy, but produce the same estrogen-deprivation side-effects as the surgical 
procedure. A few studies have examined the effect of the GnRH analogues in unselected 
postmenopausal women with metastatic breast cancer [54-56]. No significant adverse reactions, in 
particular no hot  flushes, were observed [54-56], but the therapeutic response in these unselected 
patients  was low (16-20%) [55], so treatment with the analogues has not been recommended by 
these authors.  On the other hand, if the GnRH analogue treatment were offered to postmenopausal 
women with elevated testosterone levels, one might expect a much higher percentage of responders.  
Adverse effects of  GnRH analogues in premenopausal women are the consequence of premature 
ovarian failure induced by the therapy. They are generally of low or moderate intensity but  
 a high intensity of one or more menopause-like disturbances has been reported in 3.9%  to 16.3% 
of premenopausal breast cancer patients treated with the analogues [57, 58, 60].  Such negative side 
effects should not occur in women who are already postmenopausal.    
Decrease of bone mineral density and increased risk of osteoporosis are common consequences of 
ovarian suppression in premenopausal women. FSH stimulates aromatase activity in the ovarian 
follicles, the principal site of estrogen production in premenopausal women. After the menopause, 
ovarian follicles disappear and estrogen production occurs only in peripheral tissues, including the 
adipose tissue that is the main source of estrogens at this age. In the adipose tissue, aromatase 
activity is unaffected by FSH and is stimulated by glucocorticoids [63-68]. Therefore, inhibition of 
the synthesis of gonadotropins by GnRH analogues does not influence estrogen production in 
postmenopausal women and should not adversely affect  the bones.  Nevertheless, bone mineral 
density should be evaluated at baseline and regularly checked  during the follow-up of a breast 
cancer prevention study in postmenopausal women.   
Injecton-site and allergic reactions of low or moderate intensity were seen in 5% to7% of 
premenopausal early breast cancer patients treated with GnRH analogues [61]. Severe events were 
virtually absent (0.5% of allergic reaction of 3rd or 4th degree) [61]. 
 
Summary 
Inhibition of endogenous estrogen production and activity in healthy women at increased risk of 
breast cancer is effective in reducing cancer incidence but is associated with negative side-effects.  
We suggest the following approach: 1. Elderly postmenopausal women at high risk for breast 
cancer should be screened for elevated blood testosterone levels. 2. Since the source of such 
elevation is ovarian stromal hyperplasia, the women with high levels should be offered “medical 
oophorectomy” with long-acting GnRH analogues. 3. Testosterone levels should be measured 
during the treatment in order to evaluate its effectiveness and provide a rationale for continuing it.  
Overall, the available data suggest that GnRH analogues can be used safely and with few side-
effects for breast cancer prevention in postmenopausal women, but the paucity of information 
available about the results of such use mandates caution and close follow-up. 
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